NCT06557213Not yet recruiting
a Cohort Study (Gut Microbiota and HCC)
Prediction of Liver Cancer Treatment Response Based on Gut Microbiota: a Cohort Study
Source: ClinicalTrials.gov · Last updated 16 Aug 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To analyze the predictive role of intestinal microbiota in tyrosine kinase inhibitors (TKIs) combined with immunotherapy response in patients with intermediate and advanced liver cancer.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 7 Aug 2024
- Start date
- 30 Aug 2024
- Primary completion date
- 20 May 2026
- Lead sponsor
- Xu Yong, MD
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06557213
What you commit to
- Study type: Observational
- Planned participants: 100
- From 30 Aug 2024 to the primary completion date, 20 May 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received attenuated live vaccine within 4 weeks prior to enrollment or planned during the study period
- Uncontrolled concurrent diseases
- Currently conducting clinical trials for other drugs
Other illness
- Active, known or suspected autoimmune diseases
- Known history of primary immunodeficiency
- Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation
Other
- Pregnant or lactating female patients
- Other patients deemed unsuitable for inclusion by researchers
Who the study is looking for
- Age 18-75 years old, gender unlimited
- Diagnosed as HCC through pathological or clinical examination
- BCLC Phase B or C
- Previously without systematic treatment
- Irremovable
- Intended to receive targeted anti-angiogenic drugs combined with immune checkpoint inhibitors for treatment
- ≥ 1 measurable lesion (RECIST V1.1)
- ECOG PS 0-1
- The subjects voluntarily joined this study, signed an informed consent form, had good compliance, and cooperated with follow-up.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.